Janux Therapeutics (NASDAQ: JANX) revenue
Janux Therapeutics reported revenue of $10.0m for fiscal 2025, 5.6% less than in fiscal 2024 ($10.6m).
Janux Therapeutics's best year of the last 6 was fiscal 2024. The biggest drop was in fiscal 2023, −6.1%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $10.0m | −5.6% | −$157.7m | −1,576.7% |
| 2024 | $10.6m | +31.0% | −$98.8m | −933.6% |
| 2023 | $8.1m | −6.1% | −$73.0m | −902.9% |
| 2022 | $8.6m | +136.8% | −$67.1m | −779.0% |
| 2021 | $3.6m | — | −$32.9m | −905.4% |
| 2020 | $0.0m | — | −$4.8m | — |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Janux Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Janux Therapeutics ranks 367th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Janux Therapeutics, −5.6%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 365th | Caribou Biosciences | $11.2m | 11.7% |
| 366th | Crescent Biopharma | $10.8m | — |
| 367th | Janux Therapeutics | $10.0m | −5.6% |
| 368th | Zenas BioPharma | $10.0m | 100.0% |
| 369th | Taysha Gene Therapies | $9.8m | 17.3% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Janux Therapeutics
- How much revenue did Janux Therapeutics make in fiscal 2025?
- Janux Therapeutics reported revenue of $10.0m for fiscal 2025, compared with $10.6m in fiscal 2024.
- What was the best year for revenue at Janux Therapeutics?
- Of its last 6 fiscal years, fiscal 2024, with $10.6m.
- Where does Janux Therapeutics rank in its sector by revenue?
- It ranks 367th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Janux Therapeutics come from?
- From the annual report (Form 10-K) that Janux Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Janux Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Janux Therapeutics: the Janux Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.